Online inquiry

IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1231MR)

This product GTTS-WQ1231MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TPBG gene. The antibody can be applied in Renal Cell Carcinoma (RCC), Non-small lung carcinoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Mus musculus
RefSeq NM_001166392.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7162
UniProt ID Q13641
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ1231MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13891MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-2176
GTTS-WQ2264MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ALX-0171
GTTS-WQ14457MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ12919MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ8464MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HTI-1088
GTTS-WQ13208MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-04950615
GTTS-WQ2451MR IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 157
GTTS-WQ15219MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA TACI-Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW